Author

P. M. Lieberman

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 1 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 4 Organism:human· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Approach:statistical model· 3 Assay:ChIP-seq· 2 Research Focus:chromatin & epigenetic regulation· 2 Assay:DNA methylation· 2

Frequent Co-Authors

F. Lu· 2 shared A. Kossenkov· 1 shared A. Sobotka· 1 shared A. Thomas-Tikhonenko· 1 shared C. D. Falkenstein· 1 shared C. Schmidt· 1 shared C. Su· 1 shared D. Maestri· 1 shared

Activity by Year

2020-2023 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 14 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersMicrobiology

F. Lu

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

PARP1 Inhibition Halts EBV+ Lymphoma Progression by Disrupting the EBNA2/MYC Axis

G. Napoletani, S. S. Soldan, T. Kannan, S. Preston-Alp, P. Vogel, D. Maestri, L. B. Caruso, A. Kossenkov, A. Sobotka, P. M. Lieberman, I. Tempera

This study shows that PARP1 inhibition reduces EBV-driven lymphoma progression by disrupting the EBNA2/MYC axis in a mouse model.

bioRxiv · Jul 5, 2023 · PreprintCancer Biology

Alternative splicing of its 5'-UTR limits CD20 mRNA translation and enables resistance to CD20-directed immunotherapies

Z. Ang, L. Paruzzo, K. E. Hayer, C. Schmidt, M. Torres Diz, F. Xu, U. Zankharia, Y. Zhang, S. Soldan, S. Zheng, C. D. Falkenstein, J. P. Loftus, S. Y. Yang, M. Asnani, P. King Sainos, , A. Thomas-Tikhonenko

This study identifies alternative splicing of CD20 mRNA that generates translation-deficient isoforms, contributing to resistance to CD20-directed immunotherapies.

bioRxiv · Feb 19, 2023Immunology

Epigenetic Landscape of HIV Infection in Primary Human Macrophage

F. Lu, Y. Yi, O. Vladimirova, U. Zhankharia, R. Collman, P. M. Lieberman

This study examines the epigenetic changes in HIV-infected primary human macrophages, revealing a unique non-canonical bivalent epigenetic state and active viral transcription despite heterochromatin marks.

bioRxiv · Jan 25, 2022Microbiology

Reactivation of Epstein Barr Virus from Latency Involves Increased RNA Polymerase Activity at CTCF Binding Sites On The Viral Genome

L. E. M. Dunn, F. Lu, C. Su, P. M. Lieberman, J. D. Baines

This paper maps RNA polymerase activity during EBV latency and reactivation, finding that CTCF binding sites are key for early bidirectional transcription during reactivation.

bioRxiv · Nov 1, 2021Microbiology

CTCF-mediated Genomic Effects of BART Region on Epstein-Barr Virus Chromatin 3D Structure in Gastric Carcinoma Cells

K.-D. Kim, S. Cho, T. Kim, S. Huh, L. Kim, H. Tanizawa, J.-H. Shin, T. Kanda, K. J. Won, P. M. Lieberman, H. Cho, H. Kang

This study investigates how CTCF binding at the BARTp site regulates EBV 3D genome structure and gene expression in EBVaGC cells, showing its role in DNA looping and viral infectivity.

bioRxiv · Dec 3, 2020 · PreprintMicrobiology